RecruitingPhase 2NCT05975983
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
Studying Idiopathic pulmonary fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- InSilico Medicine Hong Kong Limited
- Intervention
- INS018_055(drug)
- Enrollment
- 40 enrolled
- Eligibility
- 40 years · All sexes
- Timeline
- 2024 – 2026
Study locations (12)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- HonorHealth Research Institute, Scottsdale, Arizona, United States
- Keck School of Medicine of USC, Los Angeles, California, United States
- Florida Lung Asthma and Sleep Specialist, Celebration, Florida, United States
- Central Florida Pulmonary Group, P.A. (CFPG) - Downtown Orlando, Orlando, Florida, United States
- Southeastern Research Center, Winston-Salem, North Carolina, United States
- University of Oklahoma Health Sciences Center (OUHSC), Oklahoma City, Oklahoma, United States
- Temple University Hospital-Temple Lung Center, Philadelphia, Pennsylvania, United States
- Bogan Sleep Consultants, LLC, Columbia, South Carolina, United States
- University of Texas Southwestern Medical Center, Dallas, Texas, United States
- Metroplex Pulmonary and Sleep Center, McKinney, Texas, United States
- Research Centers of America, McKinney, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05975983 on ClinicalTrials.govOther trials for Idiopathic pulmonary fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05988463Dose-Escalation Study of Artesunate Patients With IPFJoseph C. Wu
- RECRUITINGNANCT07482917Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 TrialHospital de Granollers
- RECRUITINGNANCT07486206Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 TrialHospital de Granollers
- RECRUITINGPHASE2NCT06241560A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodBoehringer Ingelheim
- RECRUITINGPHASE3NCT07201922A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisBoehringer Ingelheim
- RECRUITINGNANCT07466420Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.Katerina M. Antoniou
- RECRUITINGPHASE3NCT07299695Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary FibrosisArgyrios Tzouvelekis
- RECRUITINGPHASE2NCT07284459Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisContineum Therapeutics